Imatinib as a paradigm of targeted cancer therapies [electronic resource] / Brian J. Druker.
Material type:
FilmSeries: Henry Stewart talksBiomedical & life sciences collection. Signal transduction via protein tyrosine kinase receptors : structures, function, regulation, mechanisms and role in disease: ; Henry Stewart talksBiomedical & life sciences collection. Small molecule drug discovery: Publisher: London : Henry Stewart Talks, 2007Description: 1 online resource (1 streaming video file (38 min.) : color, sound)Subject(s): Antineoplastic agents | Cellular signal transduction | Chronic myeloid leukemia -- Chemotherapy | Protein kinases -- Inhibitors | Antineoplastic Agents -- pharmacology | imatinib | Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy | Molecular Targeted Therapy | Receptor Protein-Tyrosine Kinases | Signal TransductionOnline resources: Click here to access online | Series (Signal transduction via protein tyrosine kinase receptors) | Series (Small molecule drug discovery) Animated audio-visual presentation with synchronized narration.
Title from title frames.
Contents: Clinical description of chronic myeloid leukemia (CML) -- Molecular pathogenesis of CML -- The BCR-ABL tyrosine kinase as a therapeutic target -- Preclinical and clinical development of the ABL tyrosine kinase inhibitor, imatinib -- Mechanisms of resistance to imatinib -- Development of novel ABL tyrosine kinase inhibitors for imatinib-resistant CML -- Imatinib and gastrointestinal stromal tumor -- Extending the imatinib paradigm -- Lessons learned from the clinical trials of imatinib.
Access restricted to subscribers.
Mode of access: World Wide Web.